Petros Pharmaceuticals, Inc.
PTPI
$0.01
$0.001.41%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 725.40K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 725.40K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 391.50K | 990.70K | 1.80M | 1.46M | 577.60K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 391.50K | 990.70K | 1.80M | 1.46M | 577.60K |
| Operating Income | -391.50K | -990.70K | -1.80M | -1.46M | -577.60K |
| Income Before Tax | -336.50K | -922.70K | -2.04M | -1.20M | -552.80K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -336.50K | -922.70K | -2.04M | -1.20M | -552.80K |
| Earnings from Discontinued Operations | 0.00 | -- | 7.47M | -1.06M | -8.72M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -336.50K | -922.70K | 5.43M | -2.26M | -9.27M |
| EBIT | -391.50K | -990.70K | -1.80M | -1.46M | -577.60K |
| EBITDA | 316.30K | -282.90K | -1.09M | -750.50K | 78.50K |
| EPS Basic | 0.04 | -0.03 | -1.29 | -9.37 | -26.68 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.05 | -0.65 | -0.85 |
| EPS Diluted | 0.04 | -0.03 | -1.29 | -9.37 | -26.68 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.05 | -0.65 | -0.85 |
| Average Basic Shares Outstanding | 42.44M | 42.28M | 25.92M | 1.16M | 404.30K |
| Average Diluted Shares Outstanding | 42.44M | 42.28M | 25.92M | 1.16M | 404.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |